Cargando…

Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects

Immune-checkpoint blockade (ICB) demonstrated inspiring effect and great promise in anti-cancer therapy. However, many obstacles, such as drug resistance and difficulty in patient selection, limited the efficacy of ICB therapy and awaited to be overcome. By timely identification and intervention of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Tianhang, Liu, Tianyao, Zhu, Wenjie, Xie, Shangxun, Zhao, Zihan, Feng, Baofu, Guo, Hongqian, Yang, Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365012/ https://www.ncbi.nlm.nih.gov/pubmed/34408525 http://dx.doi.org/10.1177/11795549211035540

Ejemplares similares

The combination of oxaliplatin and anti-PD-1 inhibitor promotes immune cells infiltration and enhances anti-tumor effect of PD-1 blockade in bladder cancer
por: Zhao, Zihan, et al.
Publicado: (2023)

Preoperative Risk Classification Using Neutrophil-to-Lymphocyte Ratio and Albumin for Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy
por: Zhao, Zihan, et al.
Publicado: (2020)

Antifungal immunity mediated by C-type lectin receptors may be a novel target in immunotherapy for urothelial bladder cancer
por: Li, Tianhang, et al.
Publicado: (2022)

Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade
por: Conche, Claire, et al.
Publicado: (2023)

A comparative study of perioperative and survival outcomes of robot-assisted radical cystectomy in patients over 80 and under 80 years old
por: Xie, Shangxun, et al.
Publicado: (2021)

Circular RNA FAM114A2 suppresses progression of bladder cancer via regulating ∆NP63 by sponging miR-762
por: Liu, Tianyao, et al.
Publicado: (2020)

The Lymph Node Microenvironment May Invigorate Cancer Cells With Enhanced Metastatic Capacities
por: Li, Tianhang, et al.
Publicado: (2022)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013)

A potential biological signature of 7-methylguanosine-related lncRNA to predict the immunotherapy effects in bladder cancer
por: Xie, Shangxun, et al.
Publicado: (2023)

Analysis and identification of the necroptosis landscape on therapy and prognosis in bladder cancer
por: Zhao, Zihan, et al.
Publicado: (2022)

Evaluating adipose‐derived stem cell exosomes as miRNA drug delivery systems for the treatment of bladder cancer
por: Liu, Tianyao, et al.
Publicado: (2022)

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
por: Li, Xiaolei, et al.
Publicado: (2018)

MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers
por: Fultang, Livingstone, et al.
Publicado: (2019)

Immunosuppressive capacity of circulating MDSC predicts response to immune checkpoint inhibitors in melanoma patients
por: Petrova, Vera, et al.
Publicado: (2023)

Neutrophils and Granulocytic MDSC: The Janus God of Cancer Immunotherapy
por: Zilio, Serena, et al.
Publicado: (2016)

Landscape of Immunotherapy Options for Colorectal Cancer: Current Knowledge and Future Perspectives beyond Immune Checkpoint Blockade
por: Gorzo, Alecsandra, et al.
Publicado: (2022)

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond
por: Lee, Yun Hua, et al.
Publicado: (2020)

Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade
por: Davidson, Tara, et al.
Publicado: (2022)

A Pan-Cancer Immunogenomic Atlas for Immune Checkpoint Blockade Immunotherapy
por: Yang, Jing, et al.
Publicado: (2022)

Mechanisms underlying response and resistance to immune checkpoint blockade in cancer immunotherapy
por: Lee, Junghwa, et al.
Publicado: (2023)

Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
por: Roy, Dia, et al.
Publicado: (2023)

Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade
por: Lei, Yanna, et al.
Publicado: (2021)

Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma
por: Zhang, Na, et al.
Publicado: (2020)

Prospects for combining immune checkpoint blockade with PARP inhibition
por: Li, Anping, et al.
Publicado: (2019)

CD8+CD39+ T Cells Mediate Anti-Tumor Cytotoxicity in Bladder Cancer
por: Zhu, Wenjie, et al.
Publicado: (2021)

Prediction of immune infiltration and prognosis for patients with urothelial bladder cancer based on the DNA damage repair-related genes signature
por: Li, Tianhang, et al.
Publicado: (2023)

Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies
por: Hegde, Upendra P., et al.
Publicado: (2017)

Epigenetic checkpoint blockade: new booster for immunotherapy
por: Wang, Ziqiao, et al.
Publicado: (2021)

A novel strategy for modulation of MDSC to enhance cancer immunotherapy
por: Ghansah, Tomar
Publicado: (2012)

Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy
por: Sun, Shangqin, et al.
Publicado: (2021)

Targeting Metabolism to Control Immune Responses in Cancer and Improve Checkpoint Blockade Immunotherapy
por: Luby, Angèle, et al.
Publicado: (2021)

Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy
por: Zhao, Peiqi, et al.
Publicado: (2022)

Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma
por: Zeng, Zhu, et al.
Publicado: (2020)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

Catechins and antitumor immunity: Not MDSC’s cup of tea
por: Santilli, Giorgia, et al.
Publicado: (2013)

Nanosonosensitizer-Augmented Sonodynamic Therapy Combined with Checkpoint Blockade for Cancer Immunotherapy
por: Lin, Xiaoning, et al.
Publicado: (2021)

Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
por: Shin, Min Hwa, et al.
Publicado: (2020)

Immune Checkpoint Blockade in Gastrointestinal Cancers: The Current Status and Emerging Paradigms
por: Miljanic, Mihailo, et al.
Publicado: (2020)

Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy
por: Adachi, Keishi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ccg7np3o83bt3290m3qih76lh7